Page 73 - தேசிய விரிவான புற்றுநோய் வலைப்பின்னல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Trastuzumab deruxtecan recommended for approval in the EU by CHMP

Recommendation based on positive results from the DESTINY-Breast01 trial, which showed durable responses in patients with previously treated disease AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s trastuzumab deruxtecan has been recommended for conditional marketing authorisation in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens. In Europe, approximately 520,000 cases of breast cancer in women are diagnosed annually, with roughly one in five cases being HER2 positive. 1-2 The impact of the disease is significant, with breast cancer responsible for more than 137,000 deaths per year.

United kingdomSan antonioUnited statesTrentino alto adigeDaiichi sankyoMelo gagliatoCompany on twitterDaiichi sankyo companyOncology developmentEuropean commissionDrug administrationWorld health organizationMerck co incInvestor relations teamEuropean unionEuropean medicines agency

Clinical Challenges: Essential Thrombocythemia

email article Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm (MPN) characterized by an increase in the number of platelets in the blood. Of the three main types of MPNs (ET, polycythemia vera, and myelofibrosis), ET is the most common, with an incidence of about 2.2 per 100,000 population yearly, according to the Leukemia and Lymphoma Society. It is driven primarily by molecular change in three genes JAK2, CALR, or MPL mutation, said Ruben Mesa, MD, director of the UT Health San Antonio MD Anderson Cancer Center. Clinically, the burden these patients face is a risk of blood clots or bleeding, the potential of elevated counts, as well as the development of disease-related symptoms.

United statesMayo clinic in rochesterNaseema gangatRuben mesaLymphoma societyNational comprehensive cancer networkManderson cancerMayo clinicEssential thrombocythemiaClinical oncologyஒன்றுபட்டது மாநிலங்களில்மயோ சிகிச்சையகம் இல் ரோசெஸ்டர்நசீமா கங்கைரூபன் மீசாலிம்போமா சமூகம்தேசிய விரிவான புற்றுநோய் வலைப்பின்னல்

EAU 2014 - Active surveillance in 853 men with low and intermediate risk prostate cancer

EAU 2014 - Active surveillance in 853 men with low and intermediate risk prostate cancer
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.

British columbiaNational comprehensive cancer networkபிரிட்டிஷ் கொலம்பியாதேசிய விரிவான புற்றுநோய் வலைப்பின்னல்

GSRGT 2020: Aggressive Surgical Approach For Tumors

GSRGT 2020: Aggressive Surgical Approach for Tumors (UroToday.com) To discuss aggressive surgical approaches for primary tumors, Dr. Chris Protzel joined the inaugural Global Society of Rare Genitourinary Tumors (GSRGT) 2020 Virtual Summit. Dr. Protzel notes that treatment of the primary tumor is the key to quality of life for these patients. Barriers to treatment of the primary tumor include fear (30%), social problems (35%), psychiatric problems (>50%), and sexual function concerns (77%). In line with these concerns, the National Comprehensive Cancer Network (NCCN) guidelines suggest that careful consideration should be given to penile-preserving techniques if the patient is reliable in terms of compliance and close follow-up. These techniques may include wide local excision, as well as Mohs surgery (plus reconstructive surgery) and laser therapy. Local recurrence after primary organ sparing surgery varies from 4-56% for patients with T1 disease and 4-34% for patients with T2 tu

Chris protzelGlobal society of rare genitourinary tumorsNational comprehensive cancer networkGlobal societyRare genitourinary tumorsRare genitourinary tumors virtual summitதேசிய விரிவான புற்றுநோய் வலைப்பின்னல்உலகளாவிய சமூகம்

GSRGT 2020: Evolution of Systemic Therapies and the Landscape of Clinical Trials Enrolling Patients

GSRGT 2020: Evolution of Systemic Therapies and the Landscape of Clinical Trials Enrolling Patients (UroToday.com) To discuss the evolution of systemic therapies and the landscape of clinical trials among patients with penile cancer, Dr. Philippe Spiess, the co-Course Director of the Global Society of Rare Genitourinary Tumors (GSRGT) 2020 Virtual Summit, invited Dr. Jad Chahoud, his colleague from the Moffitt Cancer Center. Dr. Chahoud started by highlighting that penile cancer is a rare disease in the US, representing 0.7% of all cancer, with high-risk HPV responsible for ~50% of all penile squamous cell carcinoma. The majority of these patients will present with localized or locally advanced disease whereby platinum-based combination chemotherapy remains the front-line therapy. The InPACT trial is actively enrolling patients to determine the frontline therapy for locally advanced penile cancer, given there have been limited treatment advancements in the last decade. Survival

United statesPatrizia giannatempoZachary klaassenDaniele raggiAndrea necchiPhilippe spiessMichaelb williamsSijin wenCurtisa pettawayWilliam osaiNicola nicolaiDanai dalianiGiuseppina calaresoMichael kincaidBju internationalAugusta university medical college of georgia